Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Neoplasm Metastasis 18Breast Neoplasms, Male 15Neoplasms 13Brain Neoplasms 11Inflammatory Breast Neoplasms 5Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Osteitis Deformans 2Lung Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Ductal, Breast 2Breast Diseases 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Patient Compliance 1Neoplastic Cells, Circulating 1Metastatic Breast Cancer With Intracranial Metastases 1Invasive Breast Cancer 1Insulin-Like Growth Factor I, Resistance To 1Her2 Positive Metastatic Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-Positive Early Stage Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER2 Positive Breast Cancer 1

Interventions

Trastuzumab 4pyrotinib 3Vinorelbine 2pertuzumab 1copanlisib 1Lapatinib 1Docetaxel 1Carboplatin 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Positive Breast Cancer × Lapatinib × Breast × Clear all
NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Sun Yat-sen University

Phase 2 Completed
159 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡